Project Grant R21AI194089
Award Date 7/20/26
Completion Date 6/30/28
Dollars Obligated $267K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98101, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded $2.684 million to Benaroya Research Institute at Virginia Mason on February 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct deep analysis of epitope-specific CD4+ T cells before the onset of Type 1 Diabetes. The research investigates how self-reactive CD4+ T cell responses evolve in at-risk individuals prior to T1D disease onset. The project will characterize longitudinal changes in...
- The National Institute of Allergy and Infectious Diseases awarded $894,183 to Benaroya Research Institute At Virginia Mason on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a project grant exploring in vivo regulatory T cell function in Type 1 Diabetes through the lens of expanded Tregs. The funded research investigates how autoimmunity is regulated in Type 1 Diabetes, focusing on defective CD4+FOXP3+ regulatory T cells (Tregs) that likely contribute...
- The National Institute of Allergy and Infectious Diseases awarded $886,942 to Benaroya Research Institute At Virginia Mason on June 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms of commensal-specific CD8+ T cell differentiation, restraint, and dysregulation in intestinal inflammation. The award supports research into how CD8+ intraepithelial lymphocytes respond to gut microbiota under homeostasis and become dysregulated in...
- The National Institute of Allergy and Infectious Diseases awarded $489,500 to Benaroya Research Institute at Virginia Mason on February 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify molecular mechanisms that inhibit CNS resident memory T cells driving neuroinflammation in multiple sclerosis. The project investigates CNS CD4+ tissue resident memory T cells (TRM) as a reservoir of autoreactive cells that sustains MS disease activity and resists...
- The National Institute of Allergy and Infectious Diseases awarded $267,000 to the Benaroya Research Institute at Virginia Mason on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into circulating and mucosal immune cell populations affected by therapeutic interleukin-23 blockade in Crohn's disease patients treated with risankizumab. The project will quantify and characterize TH17 cells, mucosa-associated invariant T cells,...
- The National Institute of Allergy and Infectious Diseases awarded the University of Washington $191,268 on August 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the epigenetic architecture of autoimmune risk loci, with focus on multiple sclerosis and type 1 diabetes. The award funds research into noncoding genetic variants and their role in autoimmune disease susceptibility. The project uses long-read chromatin fiber sequencing techniques...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Benaroya Research Institute at Virginia Mason $302,000 on July 1, 2026, to develop a vascularized three-dimensional biomimetic microphysiological system (MPS) for isogenic modeling of immune-beta cell interactions in Type 1 Diabetes research. The recipient will adapt a proven perfusion-capable microfluidic skin-on-chip platform—a plexiglass-based chamber system with an open well, microchannel network, and inlet and...
- The National Institute of Allergy and Infectious Diseases awarded Benaroya Research Institute At Virginia Mason $496,344 on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how the DYRK1A-GP130 axis drives immune dysregulation in Down syndrome and other autoimmune conditions. The research dissects molecular mechanisms by which DYRK1A, a kinase encoded on chromosome 21, regulates differentiation of pro-autoimmunity TH17 cells and...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Minnesota a project grant of $192,500 on July 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into generation and validation of peptide-specific MHC Class I-restricted CAR regulatory T cells (CAR Tregs) as a therapeutic approach for type 1 diabetes. Type 1 diabetes results from breakdown of immunological tolerance and T cell-mediated...
- The National Institute of Allergy and Infectious Diseases awarded Seattle Children's Hospital $911,271 on August 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms regulating integration of engineered B cells in intestinal immunity and inflammation. The research aims to develop a B cell-based immunotherapy platform for treatment of inflammatory bowel disease and related immune-mediated diseases. The project focuses on long-lived plasma...